To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

This bill seeks to fundamentally alter the legal landscape surrounding medication abortion in the United States through two primary mechanisms. First, it retroactively withdraws the Food and Drug Administration's approval of mifepristone for pregnancy termination, effectively removing this medication from legal use for abortion purposes despite its decades-long approval history. Second, it creates a novel federal cause of action that would allow women to sue for harm allegedly caused by chemical abortion drugs. The legislation represents a significant federal intervention into reproductive healthcare, pharmaceutical regulation, and tort law, aiming to restrict access to medication abortion through both regulatory withdrawal and expanded civil liability. The bill's scope extends beyond mifepristone to encompass other chemical abortion drugs, though the precise definition of this category remains unclear in the provided text.

The bill's primary substantive provisions operate on two distinct legal fronts. Section 1 deems the approved application under the Federal Food, Drug, and Cosmetic Act for mifepristone, specifically for intrauterine pregnancy termination, to have been withdrawn. This provision does not require new administrative action by the FDA but instead uses legislative fiat to nullify the existing approval, creating an immediate legal effect upon enactment. Section 2 establishes a new federal tort cause of action for harm to women caused by chemical abortion drugs, including mifepristone. This tort provision creates a private right of action that would allow affected individuals to seek damages in federal court. The legislation does not specify whether this tort preempts state law claims or operates concurrently with existing state tort remedies. Critical definitional gaps exist regarding what constitutes 'harm' under the statute and which drugs beyond mifepristone qualify as 'chemical abortion drugs' subject to the tort liability framework.

The implementation framework for this legislation remains largely unspecified in the provided text. The FDA would presumably be responsible for effectuating the withdrawal of mifepristone approval, though the deemed withdrawal language suggests this occurs automatically by operation of law rather than through standard administrative procedures. For the federal tort provisions, federal district courts would serve as the forum for litigation, with jurisdiction presumably arising under federal question jurisdiction. The bill does not establish specific administrative mechanisms for processing claims, suggest any alternative dispute resolution procedures, or create a compensation fund. No reporting requirements are specified for tracking the number or outcomes of tort claims filed under the new cause of action. The absence of implementing regulations or agency guidance provisions suggests the tort framework would be developed entirely through case-by-case litigation. Enforcement of the mifepristone withdrawal would likely fall to the FDA and Department of Justice through existing drug enforcement mechanisms, though no specific compliance monitoring or enforcement provisions are detailed.

The bill would have profound and immediate impacts across multiple stakeholder groups and healthcare systems. Women seeking medication abortion would lose access to mifepristone, the most commonly used medication abortion drug in the United States, forcing reliance on surgical procedures or other methods where legally available. Healthcare providers who prescribe mifepristone or other chemical abortion drugs would face potential federal tort liability, likely creating a significant chilling effect on provision of medication abortion services even where state law permits such care. Pharmaceutical manufacturers and distributors would face both the loss of a legal market for mifepristone in pregnancy termination and exposure to federal tort claims without the traditional protections of FDA approval as a defense. The healthcare system would experience increased demand for surgical abortion procedures and potentially increased costs associated with more invasive interventions. The federal court system would bear the administrative burden of a new category of tort litigation. No cost estimates, sunset provisions, or metrics for evaluating outcomes are provided in the bill text, making fiscal impact assessment difficult beyond recognizing substantial litigation costs and healthcare system disruption.

The bill operates within a complex and contested constitutional framework. Congress's authority to withdraw FDA drug approvals and create federal tort causes of action derives from the Commerce Clause, given the interstate nature of pharmaceutical distribution and healthcare services. However, the legislation intersects with constitutional rights recognized in reproductive healthcare contexts, creating potential conflicts with substantive due process protections depending on current Supreme Court jurisprudence regarding abortion rights. The deemed withdrawal mechanism raises questions about separation of powers, as it bypasses the Administrative Procedure Act's normal processes for agency decision-making and potentially infringes on executive branch authority over drug regulation. The federal tort provision creates questions of preemption regarding state tort law and whether federal law would occupy the field or operate concurrently with state remedies. The bill does not specify a standard of liability, statute of limitations, damages caps, or other typical tort framework elements, leaving these critical issues to judicial interpretation. No explicit judicial review provisions are included, though the deemed withdrawal would likely be subject to challenge under the APA and constitutional grounds, while tort claims would proceed through normal federal civil litigation with appellate review available through the federal court system.

The legislation presents numerous constitutional, practical, and policy concerns that would likely generate immediate legal challenges and implementation difficulties. Constitutional challenges would almost certainly focus on whether Congress can legislatively withdraw an FDA approval without administrative process, potentially violating separation of powers principles and the non-delegation doctrine. The bill's interference with access to medication abortion raises substantive due process questions, though the constitutional landscape depends heavily on evolving Supreme Court precedent. The absence of clear definitions for 'chemical abortion drugs' and 'harm' creates vagueness concerns that could render the tort provisions unconstitutionally unclear. Implementation challenges include determining which drugs beyond mifepristone fall within the statute's scope, establishing causation standards for harm allegedly caused by these medications, and managing the potential flood of litigation without specified procedural frameworks. The legislation could create perverse incentives where manufacturers face liability for FDA-approved drugs used according to medical standards, potentially deterring pharmaceutical development in reproductive health. Healthcare providers may refuse to prescribe any medications that could be construed as chemical abortion drugs to avoid liability exposure, even in cases where such medications serve other legitimate medical purposes. The bill provides no transition period or grandfather provisions for women currently using mifepristone or healthcare providers with existing prescriptions, creating immediate disruption. Opposition arguments would emphasize restrictions on reproductive autonomy, interference with the doctor-patient relationship, undermining of FDA scientific expertise, creation of uncertain liability standards, and potential for increased maternal morbidity and mortality from forcing women toward less safe abortion alternatives or continuation of unwanted pregnancies.